Dennis Xia

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

Zhaoliang Huang, Xinghua Pang, Tingting Zhong et al. · Frontiers in Immunology · 2022 · 40 citations · Full text

Pharmacy, Immunology, Oncology +17

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors

Sophia Frentzas, Hui Gan, Rasha Cosman et al. · Cell Reports Medicine · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers

Yulong Zheng, Anna Rachelle Mislang, Jermaine Coward et al. · Cancer Immunology Immunotherapy · 2022 · 20 citations · Full text

Medicine, Immunology, Oncology +14

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.

Hui Gan, Jermaine Coward, Anna Rachelle Mislang et al. · Journal of Clinical Oncology · 2021 · 18 citations

Medicine, Hematology, Oncology +16

289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone

Zhaoliang Huang, Xinghua Pang, Tingting Zhong et al. · Regular and Young Investigator Award Abstracts · 2021 · 11 citations · Full text

Life Sciences, Immunology, Oncology +17